NCT05553522 2025-12-31
Tucatinib, Trastuzumab, and Capecitabine With SRS for Brain Metastases From HER-2 Positive Breast Cancer
Baptist Health South Florida
Phase 1 Terminated
Clinical Trials
4 trialsNCT05583110 2025-12-10
TrasTUCAN
Spanish Breast Cancer Research Group
Phase 2 Terminated
NCT03501979 2025-08-29
Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD
University of Alabama at Birmingham
Phase 2 Terminated
NCT05091528 2022-08-18
A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers
Silverback Therapeutics
Phase 1/2 Terminated